DSM will invest in the expansion of DSM Anti-Infectives’ production facilities
at Toansa (India). The investment will increase production of the
penicillin-related intermediate 6-APA and of active pharmaceutical ingredients
(APIs). The expansion is part of the global restructuring program at the DSM
Anti-Infectives business group that DSM announced in December 2004 with the
aim of improving profitability in the short term and retaining DSM’s leading
positions in the global market for penicillin and penicillin derivatives.
The expansion will take place in 2006 and will lead to a doubling of
production capacity for 6- APA and Amoxicillin in India. The new facilities
will be based on DSM’s proprietary production technologies. The
investment at Toansa is fully in line with DSM’s new corporate strategy Vision
2010 – Building on Strengths. An essential element of this strategy is
active expansion of DSM’s presence in emerging economies, in order to
optimally benefit from the fast growing demand in these countries.
“It is DSM Anti-Infectives’ ambition to capture the growth of the
anti-infectives market on the Asian and African continents,” says N.V.
Ramanan, President of the Business Unit DSM Anti-Infectives Asia Middle East
and Africa, headquartered in Delhi, India, who is responsible for the Toansa
site. “But the investment not only brings higher capacity. It will
also introduce our environmentally-friendly proprietary enzymatic technology
for the production of active ingredients in India. This will lead to products
with a unique, improved quality and will bring substantial value to the
customers of our businesses in the Asia region.”
DSM Anti-Infectives will market the products from the new facilities under the
PureActivesTM brand, stressing the high purity and better processing
capabilities of the enzymatically produced Amoxicillin. The new capacities are
scheduled to come on stream in phases between January and August 2006.
